Safety Profile of Particle Embolization for Treatment of Acute Lower Gastrointestinal Bleeding.


Journal

Journal of vascular and interventional radiology : JVIR
ISSN: 1535-7732
Titre abrégé: J Vasc Interv Radiol
Pays: United States
ID NLM: 9203369

Informations de publication

Date de publication:
03 2022
Historique:
received: 25 07 2021
revised: 21 10 2021
accepted: 07 11 2021
pubmed: 20 11 2021
medline: 24 3 2022
entrez: 19 11 2021
Statut: ppublish

Résumé

To assess ischemic adverse events following particle embolization when used as a second-line embolic to coil embolization for the treatment of acute lower gastrointestinal bleeding (LGIB). The single-institution retrospective study examined 154 procedures where embolization was attempted for LGIB. In 122 patients (64 men; mean age, 69.9 years), embolization was successfully performed using microcoils in 73 procedures, particles in 34 procedures, and both microcoils and particles in 27 procedures. Particles were used as second-line only when coil embolization was infeasible or inadequate. Technical success was defined as angiographic cessation of active extravasation after embolization. Clinical success was defined as the absence of recurrent bleeding within 30 days of embolization. Technical success for embolization of LGIB was achieved in 87% of the cases (134/154); clinical success rate was 76.1% (102/134) among the technically successful cases. Clinical success was 82.2% (60/73) for coils alone and 68.9% (42/61) for particles with or without coils. Severe adverse events involving embolization-induced bowel ischemia occurred in 3 of 56 (5.3%) patients who underwent particle embolization with or without coils versus zero of 66 patients when coils alone were used (P = .09). In patients who had colonoscopy or bowel resection within 2 weeks of embolization, ischemic findings attributable to the procedure were found in 3 of the 15 who underwent embolization with coils alone versus 8 of 18 who underwent embolization with particles with or without coils (P = .27). Particle embolization for the treatment of LGIB as second-line to coil embolization was associated with a 68.9% clinical success rate and a 5.3% rate of ischemia-related adverse events.

Identifiants

pubmed: 34798292
pii: S1051-0443(21)01478-0
doi: 10.1016/j.jvir.2021.11.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

286-294

Informations de copyright

Copyright © 2021 SIR. Published by Elsevier Inc. All rights reserved.

Auteurs

Elisabeth Seyferth (E)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.

Rui Dai (R)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.

James Ronald (J)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.

Jonathan G Martin (JG)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.

Alan A Sag (AA)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.

Nicholas Befera (N)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.

Waleska M Pabon-Ramos (WM)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.

Paul V Suhocki (PV)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.

Tony P Smith (TP)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina.

Charles Y Kim (CY)

Division of Interventional Radiology, Duke University Medical Center, Durham, North Carolina. Electronic address: charles.kim@duke.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH